Shanghai Junshi Biosciences Co (HKSE:01877) Accounts Receivable : HK$534.5 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Shanghai Junshi Biosciences Co's accounts receivables for the quarter that ended in Mar. 2024 was HK$534.5 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Shanghai Junshi Biosciences Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 117.91.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Shanghai Junshi Biosciences Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was HK$0.04.

Shanghai Junshi Biosciences Co Accounts Receivable Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Accounts Receivable Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

175.17

786.33

1,583.15

259.89

524.71

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial														-	529.77	-	524.71	534.55

Shanghai Junshi Biosciences Co Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Shanghai Junshi Biosciences Co Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Shanghai Junshi Biosciences Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	534.547	/	413.668	*	91
=	117.91

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Shanghai Junshi Biosciences Co's accounts receivable are only considered to be worth 75% of book value:

Shanghai Junshi Biosciences Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(4952.785	+	0.75 * 534.547	+	0.5 * 581.767	-	5437.669
-	0	-	165.951)	/	985.69
=	0.04

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Shanghai Junshi Biosciences Co Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Executives

Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Highbury Investment Pte Ltd	2101 Beneficial owner
Jovial Champion Investments Limited	2201 Interest of corporation controlled by you
Gong Ruilin	2202 Interest of your spouse
Vistra Trust (singapore) Pte. Limited	2201 Interest of corporation controlled by you
Lvc Holdings Limited	2201 Interest of corporation controlled by you
Lvc Management Holdings Limited	2201 Interest of corporation controlled by you
Lvc Innovate Limited	2201 Interest of corporation controlled by you
Lin Lijun	2307 Founder of a discretionary trust who can infl
Lvc Renaissance Fund Lp	2101 Beneficial owner
Lvc Renaissance Limited	2201 Interest of corporation controlled by you
Loyal Valley Innovation Capital (hk) Limited	2201 Interest of corporation controlled by you
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines